Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort A: AK104 | Experimental | AK104 monotherapy |
|
| Cohort B: AK104+chemotherapy | Experimental | AK104 combined with platinum-based chemotherapy (paclitaxel+ cisplatin or carboplatin) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AK104 | Drug | AK104 15mg/kg intravenously(IV) every 3 weeks (Q3W), until progressive disease, unacceptable toxicity, completion of 2 years treatment or withdrawal of consent. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Objective response rate (ORR) assessed by investigator. | The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1 | Up to approximately 1 years |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival (PFS) Assessed by investigator | The time from the first administration to the first documented progressive disease (PD) or death due to any cause, whichever occurs first | Up to approximately 2 years |
| Duration of Response (DOR) Assessed by investigator |
Not provided
Inclusion Criteria:
Age >=18 and <=80. ECOG of 0 or 2. Life expectancy ≥ 3 months. Histologically confirmed vulvar cancer (squamous cell carcinoma or adenosquamous carcinoma), not amenable to curative surgery or radical radiotherapy.
For Cohort A, subjects should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy.
At least one measurable tumor lesion per RECIST v1.1. Adequate organ function as assessed in the laboratory tests. Female subjects of childbearing potential must have a negative serum pregnancy test prior to the the first administration and agree to use effective methods of contraception
Exclusion Criteria:
Subjects with other histopathological types of vulvar cancer, such as melanoma, sarcoma, etc.
Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration.
Previous treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.).
Active or potentially recurrent autoimmune disease.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ting Liu, MD | Contact | +86(0760)89873999 | clinicaltrials@akesobio.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical oncology school of Fujian Medical University, Fujian Cancer Hospital | Recruiting | Fuzhou | Fujian | 350000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014846 | Vulvar Neoplasms |
| ID | Term |
|---|---|
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D016190 | Carboplatin |
| ID | Term |
|---|---|
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| AK104+ Paclitaxel+Cisplatin or Carboplatin | Drug | AK104 (10 mg/kg) + paclitaxel (175 mg/m2)+ cisplatin (50 mg/m2) or carboplatin (AUC 4-5) , IV, Q3W, for up to 6 cycles, followed by maintenance therapy of AK104 10 mg/kg Q3W until disease progression, intolerable toxicity, withdrawal of consent, or completion of 2 years treatment. |
|
Measured from the date of partial or complete response to therapy until the disease progression per RECIST v1.1 criteria |
| Up to approximately 2 years |
| Disease control rate (DCR) Assessed by investigator | The proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥6 weeks) based on RECIST | Up to approximately 1 years |
| Time to Response (TTR) Assessed by investigator | The time from the first administration to the date of documented CR or PR | Up to approximately 1 years |
| Overall survival (OS) | The time from the first administration to death due to any cause | Up to approximately 2 years |
| Adverse Events (AEs) | Characterization of incidence, severity and abnormal clinically significant manifestation or laboratory findings. | Up to approximately 2 years |
| serum concentrations of AK104 | assessment of PK include serum concentrations of AK104 at different timepoints after study drug administration | Up to approximately 2 years |
| Antidrug antibodies (ADA) of AK104 | Proportion of subjects who develop detectable anti-drug antibodies (ADAs) | Up to approximately 2 years |
| Sun Yant-Sen Memorial Hospital | Recruiting | Guangzhou | Guangdong | 510000 | China |
|
| The Fourth Hospital of Hebei Medical University | Not yet recruiting | Shijiangzhuang | Hebei | 050000 | China |
|
| Liaoning Cancer Hospital & Insitut | Recruiting | Shenyang | Liaoning | 110042 | China |
|
| Tianjin medical university Cancer Institut & Hospital | Recruiting | Tianjin | Tianjin Municipality | 300000 | China |
|
| Zhejiang Cancer Hospital | Not yet recruiting | Hangzhou | Zhejiang | 310022 | China |
|
| D014845 |
| Vulvar Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |